enVVeno Medical Corporation
NVNO
Get informed when a big investor buys or sells
+ FollowMarket Cap$73.65M
Close$
$4.02
62.6% downside
Current Fair Value
62.6% downsideOvervalued by 62.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $73.65 Million |
|---|---|
| Enterprise Value | $71.86 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-33.06 |
| Beta | 1.09 |
| Outstanding Shares | 654,000 |
Return
| Return on Equity | -79.24% |
|---|---|
| Return on Assets | -72.11% |
| Return on Invested Capital | -83.52% |
Valuation & Multiples
| P/E Ratio | -0.39 |
|---|---|
| PEG | 2.71 |
| Price to Sales | - |
| Price to Book Ratio | 0.3 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.59 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 7, 2026
EPS Estimate
$-8.40
Average shareholder expectationRevenue Estimate
$500,000
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-9.10
Average shareholder expectationRevenue Estimate
$1.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 15.37%▼ 1123.15% |
|---|---|
| Total Invested | $1.02M▼ 51.58% |
| Investors Holding | 17▼ 20.00% |
ESG Score
No data
About enVVeno Medical Corporation
19 employeesHancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product c...